The Journal of Allergy and Clinical Immunology publishes an interesting study with a new way of allergen-specific immunotherapy (epicutaneous immunotherapy).

The clinical trial, placebo-controlled double-blind study, was aimed to optimize treatment dose and to demonstrate the efficacy and safety of epicutaneous immunotherapy. The study, that was performed by the University Hospital of Zürich (Switzerland), shows a dose-dependent response and concludes that epicutaneous allergen immunotherapy is convenient, safe and efficacious treatment for IgE-mediated allergies. The allergen extracts (MG51 6-grasses) used in the study were supplied by INMUNOTEK.

Epicutaneous allergen-specific immunotherapy ameliorates grass pollen–induced rhinoconjunctivitis: A double-blind, placebo-controlled dose escalation study

Gabriela Senti MD^{, ∗}, Seraina von Moos MD^{, ∗}, Fabian Tay MD^a, Nicole Graf PhD^a, Theodor Sonderegger MSc^c, Pål Johansen PhD^b, Thomas M. Kündig MD^{,  ,}  

a Clinical Trials Center, University Hospital Zurich, Zurich, Switzerland

b Department of Dermatology, University Hospital Zurich, Zurich, Switzerland

c Galenical Department, Cantonal Pharmacy, Canton of Zurich, Zurich, Switzerland

+ info

---